Unknown PHASE3 INTERVENTIONAL 2-arm NCT02907710

Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

Sponsor: First Affiliated Hospital of Guangxi Medical University

Conditions Nasopharyngeal Carcinoma

Interventions DDP Endostar

Updated 6 times since 2017 Last updated: Sep 15, 2016 Started: Oct 31, 2016 Primary completion: Nov 30, 2018 Completion: Nov 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02907710, this PHASE3 trial focuses on Nasopharyngeal Carcinoma and remains ongoing. Sponsored by First Affiliated Hospital of Guangxi Medical University, it has been updated 6 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Dec 2019 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Dec 2019 [monthly]

Not Yet Recruiting PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Oct 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Guangxi Medical University

Data source: First Affiliated Hospital of Guangxi Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanning, China